NKTR-214 Cover on Cancer Discovery
In the third part of our mini-series on cytokines, we get down and dirty with another pegylated IL-2 approach, this time from Nektar Therapeutics, including an interview with the PI, Dr Adi Diab from MD Anderson Cancer Centre and CSO, Dr Jonathan Zalevsky.
We’ve certainly had many full ranging discussions and chats with the good gentlemen; here we continue our journey to understand more about the science and underlying biology, as well as key biomarkers of response.
We can also be provocative too and put them on the spot regarding their critics and some of the pointed questions that get bandied about, which certainly makes for interesting reading. Are they justified?
What should we be looking for when analysing the data? You can find out for yourselves in the latest expert interview.
Other pertinent topics are also covered including where they’re headed and future data readouts to expect.
To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.
After writing about how the design aspects of antibodies can affect clinical performance recently, a few fascinated readers wrote in asking if there were more examples they could learn from.
Sure there are, and so that simple question inspired five more examples.
They range from small to large biotech/pharma, both public and private – no one has dominance in innovation chops, after all.
In this latest review we look at examples from CAR-T cell therapies, antibodies, immunocytokines and even bispecifics – there’s a lot of cool science going under the hood that many casual observers simply do not realise.
What’s more, some of the selected improvements and changes may (or may not) lead to enhancement of clinical performance down the road, so it is important to pay attention to what’s going on relative to each niche rather than be surprised and caught unaware…
To learn more and get a heads up on our latest oncology insights and R&D analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.